Articles

Inefficiency of cynarin as therapeutic regimen in familial type II hyperlipoproteinaemia.

Author

Heckers H, Dittmar K, Schmahl FW

Date

2/1977

Journal

Atherosclerosis

Abstract

Seventeen ambulant outpatients with familial Type IIa or Type IIb hyperlipoproteinaemia were treated with Cynarin, the 1,5-dicaffeyl ester of quinic acid, the constituent of the artichoke (Cynara scolymus). The dose tested was 250 mg and 750 mg daily. The mean serum cholesterol and triglyceride concentrations were not significantly changed within 3 months. Cynarin, administered per os, has no hypolipidaemic effect in familial Type II hyperlipoproteinaemia.